Its targets converge on two molecular programs: (i) attenuation of chronic neurodegeneration, exemplified by regulation of Tau pathology in Alzheimer’s disease; and (ii) acute cytoprotection against oxidative and excitotoxic stress. The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.